{"id":"W4243908687","doi":"10.1093/neuonc/noy148.988","title":"RARE-11. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED LOW-GRADE GLIOMA (LGG)","year":2018,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Dabrafenib; Medicine; Trametinib; Internal medicine; Adverse effect; Progression-free survival; Oncology; Clinical endpoint; Refractory (planetary science); Nausea; Melanoma; Glioma; MEK inhibitor; Gastroenterology; Surgery; Clinical trial; Cancer; Vemurafenib; Chemotherapy; Cancer research; Metastatic melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006518734,0.0003645261,0.0009293433,0.0002814222,0.0001616671,0.0004267551,0.0003162361,0.0004374182,0.002416269],"category_scores_gemma":[0.0006943677,0.0001910733,0.0006627075,0.000250686,0.000345611,0.0003957613,0.0002316074,0.0009851453,0.0005179222],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000502089,"about_ca_system_score_gemma":0.0005322688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007102262,"about_ca_topic_score_gemma":0.003825524,"domain_scores_codex":[0.999755,0.00009777995,0.0000257954,0.0000382441,0.00003353511,0.00004981838],"domain_scores_gemma":[0.9996165,0.00007824819,0.0001182061,0.00002447136,0.00002484675,0.0001376229],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.408448,0.01267257,0.04794082,0.002077324,0.001678471,0.001444461,0.0003811645,0.00345195,0.05955879,0.0007957352,0.008711229,0.4528396],"study_design_scores_gemma":[0.3327821,0.4967542,0.1152565,0.0003044965,0.002123272,0.006441544,0.0003194642,0.006175872,0.01977546,0.0006640715,0.01928473,0.0001183147],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921393,0.00387534,0.0002792928,0.0003239489,0.00005174164,0.0002699572,0.0008046108,0.0001252568,0.002130722],"genre_scores_gemma":[0.9963226,0.001055522,0.0005171454,0.0002842479,0.00004176773,0.0001504504,0.0009651993,0.00000704446,0.00065598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002416269,"threshold_uncertainty_score":0.008083284,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01540906434180474,"score_gpt":0.288089727165392,"score_spread":0.2726806628235873,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}